Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to reduce the thrombotic risk associated with combined oral contraceptives (COCs) from their arrival on the market until today. Evidences suggesting that COCs were associated with an increased risk of VTE appeared rapidly after their marketing. Identified as the main contributor of this risk, the dosage of the estrogen, i.e., ethinylestradiol (EE), was significantly reduced. New progestins were also synthetized (e.g., desogestrel or gestodene) but their weak androgenic activity did not permit to counterbalance the effect of EE as did the initial progestins such as levonorgestrel. Numerous studies assessed the impact of estroprogestative combinations on hemostasis and demonstrated that women under COC suffered from resistance towards activated protein C (APC). Subsequently, the European Medicines Agency updated its guidelines on clinical investigation of steroid contraceptives in which they recommended to assess this biological marker. In 2009, estradiol-containing COCs were marketed and the use of this natural form of estrogen was found to exert a weaker effect on the synthesis of hepatic proteins compared to EE. In this year 2021, a novel COC based on a native estrogen, i.e., estetrol, will be introduced on the market. Associated with drospirenone, this preparation demonstrated minor effects on coagulation proteins as compared with other drospirenone-containing COCs. At the present time, the standard of care when starting a contraception, consists of identifying the presence of hereditary thrombophilia solely on the basis of familial history of VTE. This strategy has however been reported as poorly predictive of hereditary thrombophilia. One rationale and affordable perspective which has already been considered in the past could be the implementation of a baseline screening of the prothrombotic state to provide health care professionals with objective data to support the prescription of the more appropriate contraceptive method. While this strategy was judged too expensive due to limited laboratory solutions, the endogenous thrombin potential-based APC resistance assay could now represent an interesting alternative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) · The Lancet · doi:10.1016/s0140-6736(95)91927-9 · Cited by 453
Comparison of pharmacodynamic properties of various estrogen formulations
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., & Mishell, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90218-6 · Cited by 316
Coagulation effects of oral contraception
Bonnar, J. (1987) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(87)80129-1 · Cited by 184
Impact of estrogen type on cardiovascular safety of combined oral contraceptives
Dinger, J., Do Minh, T., & Heinemann, K. (2016) · Contraception · doi:10.1016/j.contraception.2016.06.010 · Cited by 160 · cited 1×
“This suggests that EE/levonorgestrel is not the only option for minimizing the risk of VTE associated with COC use, but estradiol-containing product is equally safe (86).”
BackgroundÅgren, U. M., Anttila, M., Mäenpää-Liukko, K., Rantala, M.-L., Rautiainen, H., Sommer, W. F., & Mommers, E. (2011) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2011.604450 · Cited by 130
Estetrol: a unique steroid in human pregnancy
Holinka, C. F., Diczfalusy, E., & Coelingh Bennink, H. J. T. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.03.027 · Cited by 123 · cited 1×
“Estetrol is present in maternal blood and urine from the ninth week of gestation and reaches the maternal circulation through the placenta (88).”
BackgroundDouxfils, J., Klipping, C., Duijkers, I., Kinet, V., Mawet, M., Maillard, C., Jost, M., Rosing, J., & Foidart, J.-M. (2020) · Contraception · doi:10.1016/j.contraception.2020.08.015 · Cited by 120 · cited 1×
“Further hemostasis investigations revealed that this novel E4-containing COC had a very low impact on the coagulation and fibrinolytic systems (98).”
BackgroundSelf-citationJunge, W., Mellinger, U., Parke, S., & Serrani, M. (2011) · Clinical Drug Investigation · doi:10.2165/11590220-000000000-00000 · Cited by 107 · cited 2×
“org 9 on lipid, hemostasis and carbohydrate metabolism (75, 78).”
BackgroundMawet, M., Maillard, C., Klipping, C., Zimmerman, Y., Foidart, J.-M., & Coelingh Bennink, H. J. T. (2015) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2015.1068934 · Cited by 100
Apter, D., Zimmerman, Y., Beekman, L., Mawet, M., Maillard, C., Foidart, J.-M., & Coelingh Bennink, H. J. T. (2016) · Contraception · doi:10.1016/j.contraception.2016.04.015 · Cited by 77 · cited 3×
“In the meantime, an open-label, multi-center, randomized, dose-finding study (FIESTA) was performed to assess bleeding pattern and cycle control of E4 combined with either drospirenone or levonorgestrel (96).”
BackgroundApter, D., Zimmerman, Y., Beekman, L., Mawet, M., Maillard, C., Foidart, J.-M., & Coelingh Bennink, H. J. T. (2017) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2017.1336532 · Cited by 57 · cited 1×
“The combination of 15 mg E4 with 3 mg drospirenone proved to be the most efficacious with respect to bleeding and cycle control and showed the most satisfaction among the users (96, 97).”
BackgroundFruzzetti, F., Trémollieres, F., & Bitzer, J. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.662547 · Cited by 56 · cited 1×
“An inappropriate estrogen-progestogen ratio or a suboptimal E2 dosage was pointed out as the plausible explanation for this failure in cycle control (67, 74).”
Background
Cited by
A citizen-science-enabled catalogue of the vaginal microbiome and associated factors
Lebeer, S., Ahannach, S., Gehrmann, T., Wittouck, S., Eilers, T., Oerlemans, E., Condori, S., Dillen, J., Spacova, I., Vander Donck, L., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01500-0 · Cited by 181
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“In an umbrella review exploring the association of reproductive factors with cardiovascular disease (CVD), current use of COCs was found to be associated with an increased risk of ischemic heart disease (RR 1.6, 95%CI 1.3–1.9) and stroke (RR 1.7, 95%CI 1.5–1.9) [19].”
BackgroundInfluential
Metadata
- Authors
- Morimont, L., Haguet, H., Dogné, J.-M., Gaspard, U., & Douxfils, J.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2021-12-09
- Volume
- 12
- Pages
- 769187-769187
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W4200612021
- Cited by
- 183
- References
- 13
- FWCI
- 19.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.